CHI Advisors LLC - Q4 2021 holdings

$301 Million is the total value of CHI Advisors LLC's 20 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 5.3% .

 Value Shares↓ Weighting
RXDX SellPROMETHEUS BIOSCIENCES INC$69,283,000
+2.1%
1,752,243
-38.8%
23.00%
+16.1%
RPTX SellREPARE THERAPEUTICS INC$46,656,000
-20.4%
2,212,256
-0.9%
15.49%
-9.4%
CGEM BuyCULLINAN ONCOLOGY INC$38,215,000
-24.6%
2,476,720
+10.3%
12.68%
-14.2%
PLRX BuyPLIANT THERAPEUTICS INC$34,688,000
-17.3%
2,569,479
+3.4%
11.51%
-6.0%
LRMR  LARIMAR THERAPEUTICS INC$16,348,000
-6.4%
1,515,1480.0%5.43%
+6.4%
VECT BuyVECTIVBIO HLDG AG$13,136,000
-34.4%
2,675,408
+3.2%
4.36%
-25.4%
 OMEGA THERAPEUTICS INC$11,964,000
-39.9%
1,055,8820.0%3.97%
-31.7%
ONCR BuyONCORUS INC$11,104,000
-32.3%
2,106,903
+20.0%
3.69%
-23.0%
IKNA BuyIKENA ONCOLOGY INC$10,217,000
+157.0%
814,756
+158.7%
3.39%
+192.3%
CMPX NewCOMPASS THERAPEUTICS INC$9,585,0003,023,692
+100.0%
3.18%
ORTX BuyORCHARD THERAPEUTICS PLCads$8,514,000
-9.3%
6,449,856
+58.0%
2.83%
+3.1%
AKUS SellAKOUOS INC$7,107,000
-28.7%
836,120
-2.6%
2.36%
-18.9%
INZY SellINOZYME PHARMA INC$6,084,000
-43.0%
892,057
-3.1%
2.02%
-35.1%
KZR BuyKEZAR LIFE SCIENCES INC$4,552,000
+602.5%
272,250
+263.0%
1.51%
+699.5%
DTIL SellPRECISION BIOSCIENCES INC$4,489,000
-39.8%
606,629
-6.2%
1.49%
-31.6%
FRLN BuyFREELINE THERAPEUTICS HLDGSsponsored ads$3,715,000
-23.7%
1,876,389
+31.4%
1.23%
-13.2%
GTHX BuyG1 THERAPEUTICS INC$2,348,000
+249.9%
230,000
+360.0%
0.78%
+297.4%
OVID BuyOVID THERAPEUTICS INC$1,284,000
+63.6%
400,000
+71.3%
0.43%
+86.0%
KROS BuyKEROS THERAPEUTICS INC$1,025,000
+105.0%
17,518
+38.7%
0.34%
+132.9%
CRVS BuyCORVUS PHARMACEUTICALS INC$964,000
+20.0%
400,000
+141.1%
0.32%
+36.8%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-11
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
PRECISION BIOSCIENCES INC17Q3 202313.4%
OVID THERAPEUTICS INC17Q3 20235.8%
CORVUS PHARMACEUTICALS INC16Q2 20231.8%
KEZAR LIFE SCIENCES INC15Q1 20235.8%
PLIANT THERAPEUTICS INC14Q3 202329.2%
REPARE THERAPEUTICS INC14Q3 202330.3%
ORCHARD THERAPEUTICS PLC14Q4 202252.6%
LARIMAR THERAPEUTICS INC14Q3 20239.1%
KEROS THERAPEUTICS INC14Q3 20238.6%
INOZYME PHARMA INC13Q3 20239.4%

View CHI Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
CHI Advisors LLC Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Corvus Pharmaceuticals, Inc.February 13, 20232,384,4025.1%
Cullinan Oncology, Inc.February 13, 20233,317,5447.2%
Freeline Therapeutics Holdings plcFebruary 13, 20234,814,4197.4%
Inozyme Pharma, Inc.February 13, 20232,204,8765.5%
Larimar Therapeutics, Inc.February 13, 20233,473,3668.0%
Oncorus, Inc.February 13, 20232,367,4369.1%
Orchard Therapeutics plcFebruary 13, 20237,987,3966.3%
PLIANT THERAPEUTICS, INC.February 13, 20233,199,8926.6%
Repare Therapeutics Inc.February 13, 20232,800,1266.7%
VectivBio Holding AGFebruary 13, 20235,492,8938.8%

View CHI Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR/A2023-08-22
13F-HR2023-08-11
13F-HR2023-05-11
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13
SC 13G/A2023-02-13

View CHI Advisors LLC's complete filings history.

Compare quarters

Export CHI Advisors LLC's holdings